1. Cognitive and behavioural inhibition deficits in neurodegenerative dementias
- Author
-
Raffaella Migliaccio, Delphine Tanguy, Arabella Bouzigues, Idil Sezer, Bénédicte Batrancourt, Isabelle Le Ber, Bruno Dubois, Valérie Godefroy, Richard Levy, Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Raffaella Migliaccio is supported by 'France Alzheimer' and 'Philippe Chatrier' Foundations, and by 'Rosita Gomez association'. Delphine Tanguy is supported by École Normale Supérieure Paris-Saclay. Arabella Bouzigues is supported by 'Fondation Vaincre Alzheimer'. Raffaella Migliaccio, Richard Levy, Valérie Godefroy and Bénédicte Batrancourt are supported by 'Fondation pour la Recherche Medicale'., Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), and Jonchère, Laurent
- Subjects
Cognitive Neuroscience ,[SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior ,Experimental and Cognitive Psychology ,Disease ,Neuropsychological Tests ,Disinhibition ,Impulsivity ,050105 experimental psychology ,Article ,Progressive supranuclear palsy ,Inhibition assessment ,03 medical and health sciences ,Cognition ,0302 clinical medicine ,Alzheimer Disease ,Behavioural variant of frontotemporal dementia (bvFTD) ,medicine ,Humans ,0501 psychology and cognitive sciences ,Non pharmacological ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior ,05 social sciences ,[SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences ,medicine.disease ,Inhibition, Psychological ,Neuropsychology and Physiological Psychology ,Cognitive inhibition ,Frontotemporal Dementia ,Alzheimer's disease (AD) ,Brain correlates ,Supranuclear Palsy, Progressive ,medicine.symptom ,Psychology ,Neuroscience ,[SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,030217 neurology & neurosurgery ,Frontotemporal dementia - Abstract
International audience; Disinhibition, mainly caused by damage in frontotemporal brain regions, is one of the major causes of caregiver distress in neurodegenerative dementias. Behavioural inhibition deficits are usually described as a loss of social conduct and impulsivity, whereas cognitive inhibition deficits refer to impairments in the suppression of prepotent verbal responses and resistance to distractor interference. In this review, we aim to discuss inhibition deficits in neurodegenerative dementias through behavioural, cognitive, neuroanatomical and neurophysiological exploration. We also discuss impulsivity and compulsivity behaviours as related to disinhibition. We will therefore describe different tests available to assess both behavioural and cognitive disinhibition and summarise different manifestations of disinhibition across several neurodegenerative diseases (behavioural variant of frontotemporal dementia, Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, Huntington's disease). Finally, we will present the latest findings about structural, metabolic, functional, neurophysiological and also neuropathological correlates of inhibition impairments. We will briefly conclude by mentioning some of the latest pharmacological and non pharmacological treatment options available for disinhibition. Within this framework, we aim to highlight i) the current interests and limits of tests and questionnaires available to assess behavioural and cognitive inhibition in clinical practice and in clinical research; ii) the interpretation of impulsivity and compulsivity within the spectrum of inhibition deficits; and iii) the brain regions and networks involved in such behaviours.
- Published
- 2020
- Full Text
- View/download PDF